Phase I Evaluation of T4 CAR T-Cell Immunotherapy of Locally Advanced/Recurrent Head and Neck Cancer

Time: 1:00 pm
day: Day Two


  •  T4 immunotherapy consists of autologous T-cells that co- express a Pan-ErbB targeted CAR (T1E28z) and an IL-4 responsive chimeric cytokine receptor, 4ab
  • Cell products are manufactured from a blood draw in a 2 week closed GMP process, using IL-4 to drive expansion of transduced cells
  • Sixteen patients have received intra-tumoural T4 CAR T-cells at doses of up to 1 billion cells, without any dose-limiting toxicities and attainment of stable disease in 10 cases